US pharma group to pay €90.5mn for 8% in deal that will boost joint Lyme disease programme
Pfizer buys stake in French vaccine maker Valneva
Related Posts
Strategic Shifts in Pharma: Roche’s $50B U.S. Investment and the Looming Impact of Tariffs on M&A
As global trade tensions escalate under the Trump administration's tariff policies, Roche AG has emerged as a pivotal player in reshaping pharmaceutical manufacturing strategies. The Basel-based...
UPS Consolidates Healthcare Logistics Dominance With $1.6 Billion Andlauer Acquisition
In a strategic move that reshapes North America's healthcare logistics landscape, United Parcel Service (NYSE: UPS) announced today its definitive agreement to acquire Toronto-based Andlauer...
KKR’s $1.2 Billion Bet on Biotage: Reshaping the Life Sciences Tools Landscape
In a move signaling private equity's growing appetite for life sciences infrastructure, KKR & Co. launched a $1.2 billion cash offer for Swedish separations technology leader Biotage AB on April 22,...
Looming Pharma Tariffs Reshape Biotech Landscape: Supply Chain Upheaval and Dealmaking Pause Send Shockwaves Through Industry
The pharmaceutical and biotechnology sectors face unprecedented disruption as President Trump's proposed 10-25% tariffs on imported drugs and medical devices threaten to upend global supply chains,...